Regulation of the activity of an adeno-associated virus vector cancer vaccine administered with synthetic Toll-like receptor agonists

Vaccine

Volumn 28, Issue 50, 2010, Pages 7837-7843

  Triozzi, Pierre L ^a   Aldrich, Wayne ^a   Ponnazhagan, Selvarangan ^b  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

Dendritic cells; Melanoma; Myeloid suppressor cells; Regulatory T cells; Trp2

Indexed keywords

CANCER VACCINE; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; IMIQUIMOD; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; MELANOMA ANTIGEN; ODN 1826; RECOMBINANT ADENO ASSOCIATED VIRUS TRP2; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ADJUVANT THERAPY; ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ACTIVATION; DENDRITIC CELL; DRUG ACTIVITY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MYELOID DENDRITIC CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; TH1 CELL;

ADJUVANTS, IMMUNOLOGIC; AMINOQUINOLINES; ANIMALS; CANCER VACCINES; CELLS, CULTURED; DENDRITIC CELLS; DEPENDOVIRUS; DNA; FEMALE; INTERLEUKIN-10; MELANOMA, EXPERIMENTAL; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, REGULATORY; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 9;

EID: 78650239955     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.09.086     Document Type: Article

References (65)

1. Ponnazhagan S. Adeno-associated virus vectors for genetic immunization. Immunol Res 2002, 26:247-252.
2. Mehendale S., van Lunzen J., Clumeck N., Rockstroh J., Vets E., Johnson P.R., et al. A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine. AIDS Res Hum Retroviruses 2008, 24:873-880.
3. Cesco-Gaspere M., Zentilin L., Giacca M., Burrone O.R. Boosting anti-idiotype immune response with recombinant AAV enhances tumour protection induced by gene gun vaccination. Scand J Immunol 2008, 68:58-66.
4. Clary B.M., Coveney E.C., Blazer D.G., Philip R., Philip M., Morse M., et al. Active immunization with tumor cells transduced by a novel AAV plasmid-based gene delivery system. J Immunother 1997, 20:26-37.
5. Eisold S., Schmidt J., Ryschich E., Gock M., Klar E., von Knebel Doeberitz M., et al. Induction of an antitumoral immune response by wild-type adeno-associated virus type 2 in an in vivo model of pancreatic carcinoma. Pancreas 2007, 35:63-72.
6. Ponnazhagan S., Mahendra G., Lima J., Aldrich W.A., Jenkins C.B., Ren C., et al. Augmentation of antitumor activity of a recombinant adeno-associated virus carcinoembryonic antigen vaccine with plasmid adjuvant. Hum Gene Ther 2004, 15:856-864.
7. Scheerlinck J.Y. Genetic adjuvants for DNA vaccines. Vaccine 2001, 19:2647-2656.
8. Smorlesi A., Papalini F., Orlando F., Donnini A., Re F., Provinciali M. Imiquimod and S-27609 as adjuvants of DNA vaccination in a transgenic murine model of HER2/neu-positive mammary carcinoma. Gene Ther 2005, 12:1324-1332.
9. Ghosh T.K., Mickelson D.J., Solberg J.C., Lipson K.E., Inglefield J.R., Alkan S.S. TLR-TLR cross talk in human PBMC resulting in synergistic and antagonistic regulation of type-1 and 2 interferons, IL-12 and TNF-alpha. Int Immunopharmacol 2007, 7:1111-1121.
10. Whiteside T.L. Immune responses to malignancies. J Allergy Clin Immunol 2010, 125(2 Suppl. 2):S272-S283.
11. Wang R.F., Appella E., Kawakami Y., Kang X., Rosenberg S.A. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med 1996, 184:2207-2216.
12. Steitz J., Brück J., Steinbrink K., Enk A., Knop J., Tüting T. Genetic immunization of mice with human tyrosinase-related protein 2: implications for the immunotherapy of melanoma. Int J Cancer 2000, 86:89-94.
13. Parkhurst M.R., Fitzgerald E.B., Southwood S., Sette A., Rosenberg S.A., Kawakami Y. Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res 1998, 58:4895-4901.
14. Samulski R.J., Chang L.-S., Shenk T. A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication. J Virol 1987, 61:3096-3101.
15. Ren C., Kumar S., Shaw D.R., Ponnazhagan S. Genomic stability of self-complementary adeno-associated virus 2 during early stages of transduction in mouse muscle in vivo. Hum Gene Ther 2005, 16:104-757.
16. Zolotukhin S., Byrne B.J., Mason E., Zolotukhin I., Potter M., Chesnut K., et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther 1999, 6:973-985.
17. Serafini P., Meckel K., Kelso M., Noonan K., Califano J., Koch W., et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 2006, 203:2691-2702.
18. Facciabene A., Aurisicchio L., Elia L., Palombo F., Mennuni C., Ciliberto G., et al. DNA and adenoviral vectors encoding carcinoembryonic antigen fused to immunoenhancing sequences augment antigen-specific immune response and confer tumor protection. Hum Gene Ther 2006, 17:81-92.
19. Kelly M.E., Zhuo J., Bharadwaj A.S., Chao H. Induction of immune tolerance to FIX following muscular AAV gene transfer is AAV-dose/FIX-level dependent. Mol Ther 2009, 17:857-863.
20. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002, 20:709-760.
21. Honda K., Yanai H., Negishi H., Asagiri M., Sato M., Mizutani T., et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005, 434:772-777.
22. Kline J., Brown I.E., Zha Y.Y., Blank C., Strickler J., Wouters H., et al. Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma. Clin Cancer Res 2008, 14:3156-3167.
23. Kujawski M., Kortylewski M., Lee H., Herrmann A., Kay H., Yu H. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest 2008, 118:3367-3377.
24. Fontenot J.D., Rudensky A.Y. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol 2005, 6:331-337.
25. Bronte V., Zanovello P. Regulation of immune responses by l-arginine metabolism. Nat Rev Immunol 2005, 5:641-654.
26. Mills C.D., Shearer J., Evans R., Caldwell M.D. Macrophage arginine metabolism and the inhibition or stimulation of cancer. J Immunol 1992, 149:2709-2714.
27. Umemura N., Saio M., Suwa T., Kitoh Y., Bai J., Nonaka K., et al. Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. J Leukoc Biol 2008, 83:1136-1144.
28. Chirmule N., Xiao W., Truneh A., Schnell M.A., Hughes J.V., Zoltick P., et al. Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle. J Virol 2000, 74:2420-2425.
29. Wang L., Cao O., Swalm B., Dobrzynski E., Mingozzi F., Herzog R.W. Major role of local immune responses in antibody formation to factor IX in AAV gene transfer. Gene Ther 2005, 12:1453-1464.
30. Zhang T.P., Jin D.Y., Wardrop R.M., Gui T., Maile R., Frelinger J.A., et al. Transgene expression levels and kinetics determine risk of humoral immune response modeled in factor IX knockout and missense mutant mice. Gene Ther 2007, 14:429-440.
31. Kochenderfer J.N., Chien C.D., Simpson J.L., Gress R.E. Synergism between CpG-containing oligodeoxynucleotides and IL-2 causes dramatic enhancement of vaccine-elicited CD8+ T cell responses. J Immunol 2006, 177:8860-8873.
32. Mansour M., Pohajdak B., Kast W.M., Fuentes-Ortega A., Korets-Smith E., Weir G.M., et al. Therapy of established B16-F10 melanoma tumors by a single vaccination of CTL/T helper peptides in VacciMax. J Transl Med 2007, 5:20.
33. Mahnke K., Qian Y., Fondel S., Brueck J., Becker C., Enk A.H. Targeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in mice. Cancer Res 2005, 65:7007-7012.
34. Davila E., Kennedy R., Celis E. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res 2003, 63:3281-3288.
35. Hamdy S., Molavi O., Ma Z., Haddadi A., Alshamsan A., Gobti Z., et al. Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity. Vaccine 2008, 26:5046-5057.
36. Tanaka M., Kaneda Y., Fujii S., Yamano T., Hashimoto K., Huang S.K., et al. Induction of a systemic immune response by a polyvalent melanoma-associated antigen DNA vaccine for prevention and treatment of malignant melanoma. Mol Ther 2002, 5:291-299.
37. Zhu J., Huang X., Yang Y. The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice. J Clin Invest 2009, 119:2388-2398.
38. van den Boorn J.G., Konijnenberg D., Tjin E.P., Picavet D.I., Meeuwenoord N.J., Filippov D.V., et al. Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG. PLoS One 2010, 5:e10626.
39. Gao J.J., Zuvanich E.G., Xue Q., Horn D.L., Silverstein R., Morrison D.C. Cutting edge: bacterial DNA and LPS act in synergy in inducing nitric oxide production in RAW 264.7 macrophages. J Immunol 1999, 163:4095-4099.
40. Yi A.K., Yoon J.G., Hong S.C., Redford T.W., Krieg A.M. Lipopolysaccharide and CpG DNA synergize for tumor necrosis factor-alpha production through activation of NF-kappaB. Int Immunol 2001, 13:1391-1404.
41. Dalpke A.H., Frey M., Morath S., Hartung T., Heeg K. Interaction of lipoteichoic acid and CpG-DNA during activation of innate immune cells. Immunobiology 2002, 206:392-407.
42. Whitmore M.M., DeVeer M.J., Edling A., Oates R.K., Simons B., Lindner D., et al. Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity. Cancer Res 2004, 64:5850-5860.
43. Berghöfer B., Haley G., Frommer T., Bein G., Hackstein H. Natural and synthetic TLR7 ligands inhibit CpG-A- and CpG-C-oligodeoxynucleotide-induced IFN-alpha production. J Immunol 2007, 178:4072-4079.
44. Gorden K.K., Qiu X., Battiste J.J., Wightman P.P., Vasilakos J.P., Alkan S.S. Oligodeoxynucleotides differentially modulate activation of TLR7 and TLR8 by imidazoquinolines. J Immunol 2006, 177:8164-8170.
45. Ehlers M., Ravetch J.V. Opposing effects of Toll-like receptor stimulation induce autoimmunity or tolerance. Trends Immunol 2007, 28:74-79.
46. Lenert P., Brummel R., Field E.H., Ashman R.F. TLR-9 activation of marginal zone B cells in lupus mice regulates immunity through increased IL-10 production. J Clin Immunol 2005, 25:29-40.
47. Wingender G., Garbi N., Schumak B., Jüngerkes F., Endl E., von Bubnoff D., et al. Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO. Eur J Immunol 2006, 36:12-20.
48. Mellor A.L., Baban B., Chandler P.R., Manlapat A., Kahler D.J., Munn D.H. Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN type 1 signaling. J Immunol 2005, 175:5601-5605.
49. Forward N.A., Furlong S.J., Yang Y., Lin T.J., Hoskin D.W. Signaling through TLR7 enhances the immunosuppressive activity of murine CD4+CD25+ T regulatory cells. J Leukoc Biol 2010, 87:117-125.
50. Morecki S., Gelfand Y., Yacovlev E., Eizik O., Shabat Y., Slavin S. CpG-induced myeloid CD11b+Gr-1+ cells efficiently suppress T cell-mediated immunoreactivity and graft-versus-host disease in a murine model of allogeneic cell therapy. Biol Blood Marrow Transplant 2008, 14:973-984.
51. Bunt S.K., Yang L., Sinha P., Clements V.K., Leips J., Ostrand-Rosenberg S. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res 2007, 67:10019-10026.
52. Terabe M., Matsui S., Park J.M., Mamura M., Noben-Trauth N., Donaldson D.D., et al. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 2003, 198:1741-1752.
53. Seung L.P., Rowley D.A., Dubey P., Schreiber H. Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection. Proc Natl Acad Sci USA 1995, 92:6254-6258.
54. Nausch N., Galani I.E., Schlecker E., Cerwenka A. Mononuclear myeloid-derived " suppressor" cells express RAE-1 and activate natural killer cells. Blood 2008, 112:4080-4089.
55. Bergami-Santos P.C., Mariano M., Barbuto J.A. Dual role of polymorphonuclear neutrophils on the growth of Ehrlich ascites tumor (EAT) in mice. Life Sci 2004, 75:245-255.
56. Marttila-Ichihara F., Auvinen K., Elima K., Jalkanen S., Salmi M. Vascular adhesion protein-1 enhances tumor growth by supporting recruitment of Gr-1+CD11b+ myeloid cells into tumors. Cancer Res 2009, 69:7875-7883.
57. Youn J.I., Nagaraj S., Collazo M., Gabrilovich D.I. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008, 181:5791-5802.
58. Melencio L., McKallip R.J., Guan H., Ramakrishnan R., Jain R., Nagarkatti P.S., et al. Role of CD4(+)CD25(+) T regulatory cells in IL-2-induced vascular leak. Int Immunol 2006, 18:1461-1471.
59. Yamano T., Kaneda Y., Huang S., Hiramatsu S.H., Hoon D.S. Enhancement of immunity by a DNA melanoma vaccine against TRP2 with CCL21 as an adjuvant. Mol Ther 2006, 13:194-202.
60. Aldrich W.A., Ren C., White A.F., Zhou S.Z., Kumar S., Jenkins C.B., et al. Enhanced transduction of mouse bone marrow-derived dendritic cells by repetitive infection with self-complementary adeno-associated virus 6 combined with immunostimulatory ligands. Gene Ther 2006, 13:29-39.
61. Hong-Geller E., Chaudhary A., Lauer S. Targeting toll-like receptor signaling pathways for design of novel immune therapeutics. Curr Drug Discov Technol 2008, 5:29-38.
62. Kusmartsev S., Su Z., Heiser A., Dannull J., Eruslanov E., Kübler H., et al. Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res 2008, 14:8270-8278.
63. Mirza N., Fishman M., Fricke I., Dunn M., Neuger A.M., Frost T.J., et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res 2006, 66:9299-9307.
64. Rehli M. Of mice and men: species variations of Toll-like receptor expression. Trends Immunol 2002, 23:375-378.
65. Iwasaki A., Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004, 10:987-995.